Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
7
|
| pubmed:dateCreated |
1987-9-15
|
| pubmed:abstractText |
A prospective double blind trial compared the fixed combination of erythromycin-sulfisoxazole (E/S) with cefaclor in the treatment of acute otitis media. One hundred nineteen children in six centers across Canada were studied. Diagnostic tympanocentesis of 134 ears yielded 135 bacterial isolates: Streptococcus pneumoniae (42%); Haemophilus influenzae (21%); Branhamella catarrhalis (10%); Streptococcus pyogenes (5%); and other bacteria (22%). Seventy-seven percent of strains of B. catarrhalis and 14% of strains of H. influenzae were beta-lactamase producers. E/S exhibited greater in vitro activity against H. influenzae and B. catarrhalis. Twenty-three patients had bacteriologically sterile middle ear fluid. The overall clinical outcome at Days 10 and 31 was identical in both treatment groups. Otoscopic findings improved more rapidly in the E/S group than in the cefaclor group at 10 and 31 days (P less than or equal to 0.04). In cases where pre-treatment middle ear fluid was negative on routine bacterial culture, complete cure at 10 days was observed in 75% of patients treated with E/S but only in 14% of those treated with cefaclor (P = 0.02). Side effects were infrequent and comparable between the test drugs. E/S is at least as effective as cefaclor in the management of acute otitis media and may be superior, particularly for cases not yielding bacteria on routine culture.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Ampicillin,
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Bacterial Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Cefaclor,
http://linkedlifedata.com/resource/pubmed/chemical/Cephalexin,
http://linkedlifedata.com/resource/pubmed/chemical/Drug Combinations,
http://linkedlifedata.com/resource/pubmed/chemical/Erythromycin,
http://linkedlifedata.com/resource/pubmed/chemical/MK 0641,
http://linkedlifedata.com/resource/pubmed/chemical/Sulfisoxazole
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
0891-3668
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
6
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
654-60
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:3302918-Acute Disease,
pubmed-meshheading:3302918-Adolescent,
pubmed-meshheading:3302918-Ampicillin,
pubmed-meshheading:3302918-Anti-Bacterial Agents,
pubmed-meshheading:3302918-Cefaclor,
pubmed-meshheading:3302918-Cephalexin,
pubmed-meshheading:3302918-Child,
pubmed-meshheading:3302918-Child, Preschool,
pubmed-meshheading:3302918-Clinical Trials as Topic,
pubmed-meshheading:3302918-Double-Blind Method,
pubmed-meshheading:3302918-Drug Combinations,
pubmed-meshheading:3302918-Erythromycin,
pubmed-meshheading:3302918-Female,
pubmed-meshheading:3302918-Haemophilus influenzae,
pubmed-meshheading:3302918-Humans,
pubmed-meshheading:3302918-Infant,
pubmed-meshheading:3302918-Male,
pubmed-meshheading:3302918-Moraxella,
pubmed-meshheading:3302918-Otitis Media with Effusion,
pubmed-meshheading:3302918-Prospective Studies,
pubmed-meshheading:3302918-Random Allocation,
pubmed-meshheading:3302918-Recurrence,
pubmed-meshheading:3302918-Streptococcus pneumoniae,
pubmed-meshheading:3302918-Sulfisoxazole
|
| pubmed:year |
1987
|
| pubmed:articleTitle |
Comparative efficacies of erythromycin-sulfisoxazole and cefaclor in acute otitis media: a double blind randomized trial.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|